Research published in November 2014 in Molecular Cancer Therapeutics and administered at St. George’s University of London’s Department of Oncology has discovered that the use of cannabinoids, specifically delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), may be useful in treating high-grade gliomas, potentially slowing the disease’s progression.
What Are High-Grade Gliomas.
Gliomas are a sort of advanced brain cancer that are fast-growing, aggressive, and troublesome to treat. Gliomas occur in the brain and spinal cord and result from the extreme proliferation of abnormal neuroglia, cells of the nervous system that are not directly involved in signalling (as opposed to neurons). Normally, interstitial tissue work in important, adjunct roles to confirm that neurons are human action properly and with efficiency, and there are three interstitial tissue for each one vegetative cell within the body. Types of gliomas embrace astrocytomas (the most frequent type), ependymomas (the commonest brain tumor in children), and oligodendrogliomas.
There are benign gliomas (which don't invade brain tissue and may be removed if in sure locations, solely manufacturing symptoms if they start to compress necessary intromission structures) and malignant gliomas (which do invade brain tissue associated have a worse prognosis or an exaggerated probability of shortened survival). Therefore, while not all gliomas are malignant, 80% of malignant brain tumours are gliomas. In the uk, 1-year survival at identification of a finest brain tumor is three hundred and sixty five days, and 5-year survival is 100%.
For glioblastoma multiforme, an expressly aggressive high-grade glioma, the majority of patients diagnosed pass away within 1 year, and 5-year survival is only 6%. While surgery, radiation, and chemotherapy can be used in attempts to treat high-grade gliomas, there are very few to no effective treatment options that increase patient survival, and finding ways to extend the lives of patients is desperately needed.
Cannabinoids as Anticancer Agents
This is not the first time that research has shown that cannabinoids may be useful as anticancer agents. According to the authors of the research, “Numerous reports highlighting potent activity in vitro [i.e. cells investigated outside of the body] and in in vivo [i.e. cells examined inside the body] models have established it as a potential anticancer therapeutic agent in a number of cancer types through processes such as:
While the authors note that the mind-expanding nature of THC has exaggerated arguing in thought of cancer treatment with its use,” a pilot trial of its therapeutic use in patients with brain tumour multiforme (GBM), an advanced type of glioma, showed feasibility without any overt psychoactive effects.”
Additionally, CBD seems to work through similar mechanisms as THC in terms of anti-tumour effects, except it may not exert effects through receptor activation as generally as THC, and it does not cause psychoactive effects. Moreover, THC demonstrates analgesic, anti-emetic, and anti-inflammatory properties, whereas CBD possesses anti-psychotic, anti-seizure, and anti-anxiety properties. Collectively, these cannabinoids (and many more) work concurrently to create an entourage effect that is much more powerful than any single cannabinoid.
According to the researchers, “…[T]hese data add further support to the concept that cannabinoids both alone and in combination with each other, possess anticancer properties.” Given this exciting new evidence, in conjunction with the antecedently existing proof supporting the potential application of cannabinoids as antitumor/anticancer agents, increased research on the use of cannabinoids in the treatment of not only high-grade gliomas however additionally alternative sorts of cancerous growths is guaranteed and required as shortly as potential.
Disclaimer: the principles contained here is not designed nor meant to be a substitute for professional medical advice, it is only achieved for educational confidences only. You should recognise full responsibility for the way you decide on to use this info.